Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

5 In both of these LEADER subgroups, fewer patients experienced MACE with liraglutide versus placebo, although the differences did not reach statistical significance [HR for insulin with OHA at baseline 0.89 (0.74; 1.06) 95%CI ; HR for insulin without OHA at baseline 0.86 (0.63; 1.17) 95% CI ]. 5 However, the LEADER trial was not powered to detect significant differences in MACE in the post hoc analysis because of the smaller number of patients included in these subgroups versus the overall LEADER population. 5 Additionally, the observation that liraglutide reduced treatment intensification with antihyperglycaemic medications during the LEADER trial, including insulin, 5 complicates the interpretation of these data.

also in 111,027 other papers